The diagnosis of PCL was eventually established. After treatment with methotrexate, followed by external beam radiotherapy, the choroidal infiltrate was normalized on B scan.

P2, N=86, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Apr 2026 --> Jul 2026 | Trial primary completion date: Mar 2026 --> Jun 2026

P=N/A, N=76, Completed, University of Virginia | Active, not recruiting --> Completed

P3, N=348, Not yet recruiting, Assistance Publique - Hôpitaux de Paris

P=N/A, N=103117, Completed, NICHD Global Network for Women's and Children's Health | Phase classification: P3 --> P=N/A | N=6214 --> 103117

P4, N=339, Not yet recruiting, Mayo Clinic

P4, N=60, Not yet recruiting, Calliditas Therapeutics AB

P1/2, N=90, Recruiting, Assiut University | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Feb 2024 --> Dec 2024

P4, N=165, Completed, Stanford University | Recruiting --> Completed

Abiraterone combined with prednisone effectively relieves bone pain and improves PSA response rates in CRPC patients, suggesting benefits in enhancing quality of life and reducing testosterone levels without increasing adverse reactions. This therapy appears to have a safety profile comparable to that of conventional treatments.

P=N/A, N=40, Recruiting, University of British Columbia | Not yet recruiting --> Recruiting

P=N/A, N=110, Recruiting, AbbVie | Not yet recruiting --> Recruiting

P4, N=404, Active, not recruiting, Rush University Medical Center | Trial completion date: Nov 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Jan 2025

It was administered treatment based on prednisone and phototherapy with a good response. This case makes possible an outlook of the demographic data of HMF, and it allows this entity to be taken into consideration for possible differential diagnoses that are not contemplated due to the limited dissemination of knowledge about this disease. It is important to emphasize the knowledge of HMF since early diagnosis and timely treatment will improve the prognosis in our patients and prevent them from being treated incorrectly.

P=N/A, N=1550, Active, not recruiting, Aalborg University Hospital

P=N/A, N=22, Active, not recruiting, Ankara City Hospital Bilkent

P4, N=80, Recruiting, University of California, Davis | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024

P3, N=21, Completed, Everest Medicines (Singapore) Pte. Ltd. | Active, not recruiting --> Completed | N=58 --> 21 | Trial completion date: Dec 2024 --> Jul 2024

P4, N=130, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University | Phase classification: P1 --> P4

P3, N=250, Not yet recruiting, Te Whatu Ora Waikato

P3, N=610, Completed, Chiesi Farmaceutici S.p.A. | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Jun 2024

P2, N=89, Recruiting, University of Florida | Trial primary completion date: Oct 2024 --> Jan 2025

A 65-year-old woman with a past medical history of hyperlipidemia on atorvastatin for four years, type 2 diabetes, sciatica, and a prior history of endometrial cancer, presented to the emergency department due to proximal muscle weakness worsening over 2-3 months...During her hospital course, she was started on prednisone, fluids, and intravenous immunoglobulin (IVIG). Once completing two days of IVIG, the patient was discharged to rehab with rheumatology follow-up. The purpose of this case is to elucidate a rare side effect of a medication despite being on it for several years and to increase awareness and attention to an adverse effect that may one day lead to stratifying patients' risk on the medication.

CD4+CD8- T-LGLL is very rare in clinical practice, and its clinical manifestations are different from those of CD4-CD8+ T-LGLL.

SRA1 inhibits the oncogenicity of ESCC via miRNA-363-5p/LHPP axis. The SRA1/miRNA-363-5p/LHPP pathway may be a therapeutic target for ESCC.

P3, N=60, Recruiting, University of California, San Francisco | Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Jul 2025

P3, N=119, Completed, Calliditas Therapeutics AB | Active, not recruiting --> Completed | Trial completion date: Jun 2024 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Feb 2024

P3, N=100, Recruiting, St. Joseph's Healthcare Hamilton | Trial completion date: Nov 2024 --> May 2025 | Trial primary completion date: May 2024 --> Apr 2025

P4, N=230, Recruiting, University of New Mexico | Trial completion date: May 2025 --> May 2027 | Trial primary completion date: Jan 2025 --> Jan 2027

P3, N=610, Active, not recruiting, Chiesi Farmaceutici S.p.A. | Trial primary completion date: Nov 2024 --> Jun 2024

P4, N=200, Recruiting, Emory University | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024

P2, N=86, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Sep 2024 --> Dec 2024

These findings demonstrate that Abi + Chl treatment lowers autophagy levels and suppresses tumors more effectively than Abi alone.

P2, N=0, Withdrawn, University of Colorado, Denver | Completed --> Withdrawn

P4, N=184, Recruiting, Medstar Health Research Institute | Trial primary completion date: Jul 2024 --> Mar 2025

P4, N=100, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting

P3, N=50, Not yet recruiting, The Hospital for Sick Children

P1/2, N=50, Not yet recruiting, Scripps Health

P3, N=30, Active, not recruiting, Icahn School of Medicine at Mount Sinai | Recruiting --> Active, not recruiting

P3, N=30, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Oct 2024 --> Jul 2025 | Trial primary completion date: Oct 2024 --> Jul 2025

This study demonstrated Mangiferin's cardioprotective effects in autoimmune myocarditis, showing reduced oxidative stress and inflammation. Mangiferin appears promising as a treatment for acute myocarditis, but further research is needed to compare its efficacy with other treatments like Trolox and Prednisone.

Steroid-mediated ocular hypertension was induced in C57BL/6J mice with weekly injections of dexamethasone into the conjunctival fornix, and mice were then injected subconjunctivally with 6 × 109 VGs of ssAAV2-STC-1-FLAG or ssAAV2-GFP...Reduction in conjunctival TNFα was seen when comparing subconjunctivally delivered ssAAV2-STC-1-FLAG to daily topical latanoprost. Subconjunctival delivery of the STC-1 transgene with a vector system may represent a novel treatment strategy for sustained IOP reduction and improved ocular tolerability that also avoids the daily dosing requirements of currently available medications. Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.